"In the IT cohorts (14 patients), 7 of 15 (47%) [should this be 7 of 14 (50%)?] injected lesions had a reduction in tumour burden [so Partial Response?], 3 lesions were completely eradicated [so Complete Response?]."
I am happy to be corrected however I would not be quick to suggest that the two melanoma patients with eradicated lesions are Complete Responders. With BC cancer sure, it generally presents with as a single tumour so eradication would be CR, however studies indicate that approximately 6% of patients with melanoma present with 2 or more primary lesions. When considering the inclusion criteria for the trial, it is not unreasonable to conclude that the % would be higher. And the possibility is that they have specifically selected melanoma patients with multiple lesions to learn more about how cf33 affects distal tumours. This being the case, I read today's announcement that the injected lesion was eradicated, however it is not (yet) a complete response. This is why the headline read it as partial:
(20min delay)